Photo courtesy of Pexels
Welcome to The Salary Chronicles, where we’re bringing transparency to negotiation and salaries, one story at a time. We ask women to share their experiences negotiating their salary and what their advice is for others doing the same. We share these stories anonymously so they feel comfortable speaking as openly and as freely as possible.
This week we’re speaking with a woman prioritized the benefit of telecommuting so much, she almost undervalued herself in her job search.
Title: Director of Product Strategy
Original salary: $103K
New salary: $118K + 15% bonus
What was the situation?
I had been working at a company for a couple of years, and while I really enjoyed it, the commute was brutal. I commuted 3 hours each day and that left me with a really limited amount of time to spend with my kids. I was a strong employee so the company let me experiment with working from home, but I knew it wasn’t a long term solution. I felt disconnected from my co-workers in the office and had trouble actively participating in meetings when I called in. I knew that if I wanted to make my telecommuting permanent while not impeding my career progression, I needed to find a company that had a virtual workforce, rather than try to be effective as the one employee who worked from home.
Top Undervalued Stocks To Own Right Now: WildHorse Resource Development Corporation (WRD)
- [By Paul Ausick]
WildHorse Resource Development Corp. (NYSE: WRD) raised $413 million on the sale of $27.5 million at $15 per share, well below the expected range of $19 to $21. Shares popped just 0.4% for the day and closed the week down 0.9%.
Top Undervalued Stocks To Own Right Now: Staples, Inc.(SPLS)
- [By Rich Duprey]
A few years ago, office-supplies retailerStaples(NASDAQ:SPLS)and electronics store RadioShack thought they could benefit from the e-tailer’s sales prowess. Although they were losing sales regularly to Amazon, they thoughtplacing lockersin their stores could also result in the sale of an extra ream of paper or a few capacitors and potentiometers. Instead what they found was customers were simply buying their paper, ink cartridges, and electronic gadgets on Amazon and picking them up in their stores. After just a year, Staples and RadioShack abruptly ended the program.
- [By Lisa Levin]
Shares of Staples, Inc. (NASDAQ: SPLS) got a boost, shooting up 7 percent to $9.25 on chatter that the company is targeted for an acquisition. Sycamore Partners, a private equity giant, is reportedly in advanced talks to acquire the office supply retailer, Reuters reported. The deal could value Staples at more than $6 billion, a premium to Staples' valuation of $5.60 billion as of Wednesday's market close.
- [By Casey Wilson]
The company was set to merge with its last remaining rival, Staples Inc. (Nasdaq: SPLS), this year, but was denied by a federal judge on May 10 because of antitrust concerns.
- [By Ben Levisohn]
Staples (SPLS) soared to the top of the S&P 500 today on reports that the office-supplies retailer was considering selling itself.
Agence France-Presse/Getty Images
Staples gained 9.8% to $9.51 today, while the S&P 500 ticked up 0.1% to 2,360.16.
CFRA’s Efraim Levy doesn’t see a “natural buyer” for Staples but remain Buy rated anyway:
Shares are higher on an unconfirmed WSJ report that SPLS is looking at the possible sale of the company. Our fundamentally valued 12-month target of $11, applies a below historical average P/E of 12.1X our FY 18 EPS estimate, given office industry challenges. Our target has 11% upside, plus a 5.5% yield. We don’t see a natural buyer for a large physical store office supply presence, although an activist/private-equity buyer is a possibility. To make an acquisition worthwhile, a buyer would have to be more aggressive in cost cutting and use of cash flow than SPLS’s existing plan.
Staples’ market capitalization rose to $6.2 billion today from $5.7 billion yesterday. It reported a net loss of $459 million on sales of $18.2 billion in fiscal 2017.
Top Undervalued Stocks To Own Right Now: GTx Inc.(GTXI)
- [By Roberto Pedone]
One biopharmaceutical player that’s rapidly moving within range of triggering a major breakout trade is GTx (GTXI), which is dedicated to the discovery, development and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle loss and other serious medical condition. This stock has been hammered by the bears so far in 2013, with shares off sharply by 53%.
If you look at the chart for GTx, you’ll notice that this stock recently gapped down sharply from over $4 to below $1.50 a share with heavy downside volume. Following that gap down, shares of GTXI have rebounded sharply and started to uptrend, with the stock moving higher from its low of $1.31 to its recent high of $1.96 a share. During that move, shares of GTXI have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of GTXI within range of triggering a major breakout trade.
Traders should now look for long-biased trades in GTXI if it manages to break out above some near-term overhead resistance at $1.96 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.35 million shares. If that breakout triggers soon, then GTXI will set up to re-fill some of its previous gap down zone from August that started just above $4 a share. Some possible upside targets if GTXI gets into that gap with volume are $2.50 to $3 a share, or possibly even $3.50 a share.
Traders can look to buy GTXI off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $1.50 a share. One can also buy GTXI off strength once it takes out $1.96 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.